1. Home
  2. CRSP vs DAR Comparison

CRSP vs DAR Comparison

Compare CRSP & DAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • DAR
  • Stock Information
  • Founded
  • CRSP 2013
  • DAR 1882
  • Country
  • CRSP Switzerland
  • DAR United States
  • Employees
  • CRSP N/A
  • DAR N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • DAR Packaged Foods
  • Sector
  • CRSP Health Care
  • DAR Consumer Staples
  • Exchange
  • CRSP Nasdaq
  • DAR Nasdaq
  • Market Cap
  • CRSP 4.9B
  • DAR 5.9B
  • IPO Year
  • CRSP 2016
  • DAR 1994
  • Fundamental
  • Price
  • CRSP $57.68
  • DAR $32.98
  • Analyst Decision
  • CRSP Buy
  • DAR Buy
  • Analyst Count
  • CRSP 16
  • DAR 7
  • Target Price
  • CRSP $70.73
  • DAR $47.14
  • AVG Volume (30 Days)
  • CRSP 3.7M
  • DAR 2.2M
  • Earning Date
  • CRSP 08-04-2025
  • DAR 07-24-2025
  • Dividend Yield
  • CRSP N/A
  • DAR N/A
  • EPS Growth
  • CRSP N/A
  • DAR N/A
  • EPS
  • CRSP N/A
  • DAR 0.66
  • Revenue
  • CRSP $37,675,000.00
  • DAR $5,701,696,000.00
  • Revenue This Year
  • CRSP $28.31
  • DAR $4.46
  • Revenue Next Year
  • CRSP $268.05
  • DAR $4.07
  • P/E Ratio
  • CRSP N/A
  • DAR $50.11
  • Revenue Growth
  • CRSP N/A
  • DAR N/A
  • 52 Week Low
  • CRSP $30.04
  • DAR $26.00
  • 52 Week High
  • CRSP $71.13
  • DAR $43.49
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 52.32
  • DAR 33.54
  • Support Level
  • CRSP $61.13
  • DAR $32.63
  • Resistance Level
  • CRSP $69.58
  • DAR $34.85
  • Average True Range (ATR)
  • CRSP 3.89
  • DAR 1.19
  • MACD
  • CRSP -0.71
  • DAR -0.52
  • Stochastic Oscillator
  • CRSP 28.46
  • DAR 6.28

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About DAR Darling Ingredients Inc.

Darling Ingredients Inc develops and manufactures sustainable ingredients for customers in the pharmaceutical, food, pet food, fuel, and fertilizer industries. It collects and transforms all aspects of animal by-product streams into ingredients, including gelatin, fats, proteins, pet food ingredients, fertilizers. Also, the company recovers and converts used cooking oil and bakery remnants into feed and fuel ingredients. Darling has three primary business segments which are feed ingredients contributing the majority of revenue, food ingredients, and fuel ingredients. It provides grease trap services for food businesses and sells various equipment for collecting and delivering cooking oil. The company derives the majority of its revenue from customers in North America.

Share on Social Networks: